Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04698109
Other study ID # BIOMIS-DIMO
Secondary ID
Status Completed
Phase
First received
Last updated
Start date February 11, 2021
Est. completion date April 8, 2022

Study information

Verified date January 2022
Source Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a prospective, clinical, monocentric study aimed to collect biological samples and study microbiota from subjects suffering from subjects with recurrent cervicovaginitis, subjects with endometriosis, subjects with repeated implantation failures and from healthy volunteers. Microbiota is a complex consortium of microorganisms, located at the mucosal level (in particular intestinal, oral and vaginal) having a key role in human health and in the onset of several diseases. Microbiota alterations have been found in several diseases (gastrointestinal, metabolic, renal, oncological, gynaecological). The study will allow to: - Provide biological samples (faeces, saliva, vaginal, urine) from healthy volunteers and patients suffering from selected disease to the first Italian microbiota biobank; - Study microorganisms using different in vitro and in vivo techniques; - Study the link between the microbiota and the disease. This study is part of the BIOMIS project (Project Code: ARS01_01220), presented as part of the "Avviso per la presentazione di progetti di ricerca industriale e sviluppo sperimentale nelle 12 aree di specializzazione individuate dal PNR 2015-2020" and admitted to funding under the National Operational Program "Ricerca e Innovazione" 2014-2020 by directorial decree of MIUR - Department for Higher Education and Research - n. 2298 of 12 September 2018. BIOMIS includes several clinical studies that enrol patients with different pathologies to collect and store biological samples and study microbiota.


Description:

The primary aim of this monocentric study is to populate the first national microbioma biobank with biological samples (fecal, salivary, urinary and vaginsl samples) subjects suffering from selected disease disease and healthy volunteers. The secondary aim is the characterization of microorganisms of the biobank and study of the microbiota-pathology relationship using meta-omics, in vitro and in vivo approaches, The study plans to enrol 100 subjects at Policlinic of Bari, according to the inclusion/exclusion criteria. The study participation is voluntary, and the subjects have the right to withdraw from the study at any time and for any reason. During the study, 3 visits are planned: - Visit 0 (V0), including description of the objectives and procedures study, signature written informed consent, inclusion/exclusion criteria evaluation, medical examination (blood pressure measurement, abdominal and thoracic physical examination), filling in of the anamnestic questionnaire, delivery of kits for the collection of fecal, salivary and urinary material to be reported at Visit 1 and delivery of a 3-day food diary, to be completed autonomously in the days preceding the Visit 1. - Visit 1 (V1) - at least 4 days after V0, including delivery of the of the collected biological material (feces, saliva, urine), and of a 3-day food diary, filling in of the new signs and symptoms anamnestic questionnaire and collection of the vaginal swab by medical staff. - Telephone evaluation: administration of a "Food Frequency Questionnaire" to assess the subjects' alimentary habits. Standard Operative Procedures (SOP) for samples storing, transport and processing will be adopted to ensure samples stability and grant results validity and quality. Following collections, samples will be processed in different aliquots that will be used for: - routine screening; - storage in the first Italian human microbiote biobank (I.R.C.C.S. - Istituto Tumori "Giovanni Paolo II", Bari); - evaluation of the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile. Furthermore, molecular characterization of pathogenic microorganisms and pathogenic biotypes (pathovars) of commensal species of subjects with selected pathologies will be conducted. Part of the biological material will be used for animal studies on the physiopathological role of the human intestinal microbiota transplanted into mouse models of pathology and Germ-free mouse models (specific animal study protocol developed). The study foresees no more than minimal risk associated with blood sampling procedures. All the necessary measures to avoid any risks / inconveniences resulting from participation of the subject under study will be taken. The study is compliant with Good Clinical Practice. Study protocol and all related documents have been approved by approved by the Independent Ethics Committees (IEC) of the involved clinical sites. To ensure the protection and confidentiality of the participants' data, all study activities will be carried out in accordance with the European General Data Protection Regulation, Regulation (EU) 2016/679, which repeals Directive 95/46/EC.


Recruitment information / eligibility

Status Completed
Enrollment 103
Est. completion date April 8, 2022
Est. primary completion date April 8, 2022
Accepts healthy volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: HEALTHY VOLUNTEERS - healthy subjects aged between 18 and 45 years, in reproductive age - BMI between 18.5-30 - omnivorous diet - signature of the informed consent PATIENTS WITH RECIDIVING CERVIC VAGINITIS - healthy subjects aged between 18 and 45 years, in reproductive age - Patients suffering from at least 3 episodes of relapsing cervicovaginitis per year: diagnosis of anaerobic vaginitis (AV) or bacterial vaginosis (BV) or vulvo-vaginal candidiasis (VVC) based on clinical symptoms and positive microscopic examination and / or positive vaginal culture - BMI between 18.5-30 - omnivorous diet - signature of the informed consent PATIENTS WITH ENDOMETRIOSIS Inclusion criteria: - aged between 18 and 45 years, in reproductive age - patients with endometriosis: diagnosis of endometriosis carried out with transvaginal ultrasound with associated elevation of CA125 - BMI between 18.5-30 - omnivorous diet - signature of the informed consent PATIENTS WITH REPEATED IMPLANT FAILURES (RIF) Inclusion criteria: - age between 18 and 45 years in reproductive age - patients with RIF: patients who have followed PMA protocols with at least 3 failed attempts after transfer of good quality embryos - BMI between 18.5-30 - omnivorous diet - signature of the informed consent Exclusion Criteria: HEALTHY VOLUNTEERS - Current or previous infectious diseases (HAV, HBV, HCV, HIV, Cytomegalovirus, Epstein-Barr virus) - HPV positive - Chronic liver disease - History of Clostridium difficile infections - Recent (<3 months) therapy with antibiotics, immunosuppressive drugs, chemotherapy - Chronic therapy with proton pump inhibitors - Recent (<3 months) use of probiotics, laxatives or other aids (drugs / supplements) for the regulation of gastrointestinal activity - Previous history of organ / tissue transplantation - Recent onset of diarrhea - Chronic diarrhea - Chronic constipation - Previous gastrointestinal surgery (eg gastric bypass) - Recurring urinary tract infections (3 cases per year) - Previous major acute cardiovascular diseases (myocardial infarction, stroke) - Type 2 diabetes mellitus - Hypertension - eGFR (estimated glomerular filtration rate) lower than 60ml / minute and / or diagnosis of nephropathy - Chronic gastrointestinal disorders - Systemic inflammatory diseases - Suspicion, clinical diagnosis or previous history of cancer (<5 years) - Autoimmune disorders or history of chronic and systemic autoimmune disorders - Neurodegenerative disorders - Pregnancy and breastfeeding - Hormonal and / or intrauterine contraceptive therapy - Healthcare workers - Operators work with animals - Psychiatric conditions that reduce protocol compliance. Exclusion criteria: POPULATION 2 - PATIENTS WITH RECIDIVING CERVIC VAGINITIS/ POPULATION 3 - PATIENTS WITH ENDOMETRIOSIS/ POPULATION 4 - PATIENTS WITH REPEATED IMPLANT FAILURES (RIF) - Current or previous infectious diseases (HAV, HBV, HCV, HIV, Cytomegalovirus, Epstein-Barr virus) - Chronic liver disease - History of Clostridium difficile infections - Recent (<3 months) therapy with antibiotics, immunosuppressive drugs, chemotherapy - Chronic therapy with proton pump inhibitors - Recent (<3 months) use of probiotics, laxatives or other aids (drugs / supplements) for the regulation of gastrointestinal activity - Previous history of organ / tissue transplantation - Recent onset of diarrhea - Chronic diarrhea - Chronic constipation - Previous gastrointestinal surgery (eg gastric bypass) - Recurring urinary tract infections (3 cases per year) - Previous major acute cardiovascular diseases (myocardial infarction, stroke) - Type 2 diabetes mellitus - Hypertension - eGFR (estimated glomerular filtration rate) lower than 60ml / minute and / or diagnosis of nephropathy - Chronic gastrointestinal disorders - Systemic inflammatory diseases - Suspicion, clinical diagnosis or previous history of cancer (<5 years) - Autoimmune disorders or history of chronic and systemic autoimmune disorders - Neurodegenerative disorders - Pregnancy and breastfeeding - Hormonal and / or intrauterine contraceptive therapy - Healthcare workers - Operators work with animals - Psychiatric conditions that reduce protocol compliance.

Study Design


Intervention

Other:
Biological sample collection
Collection of faeces, urine, saliva, vaginal swab for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening
Questionnaire
Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
Medical examination
Blood pressure measurement, abdominal and thoracic physical examination

Locations

Country Name City State
Italy Dipartimento di Scienze biomediche e oncologia umana (DIMO), Sezione di Ginecologia ed Ostetricia II Azienda Ospedaliera Universitaria Consorziale Policlinico di Bari Bari

Sponsors (5)

Lead Sponsor Collaborator
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies, Istituti Tumori Giovanni Paolo II, University of Bari Aldo Moro, University of Salento

Country where clinical trial is conducted

Italy, 

References & Publications (4)

Laschke MW, Menger MD. The gut microbiota: a puppet master in the pathogenesis of endometriosis? Am J Obstet Gynecol. 2016 Jul;215(1):68.e1-4. doi: 10.1016/j.ajog.2016.02.036. Epub 2016 Feb 18. — View Citation

Ma D, Chen Y, Chen T. Vaginal microbiota transplantation for the treatment of bacterial vaginosis: a conceptual analysis. FEMS Microbiol Lett. 2019 Feb 1;366(4). pii: fnz025. doi: 10.1093/femsle/fnz025. Review. — View Citation

Smith SB, Ravel J. The vaginal microbiota, host defence and reproductive physiology. J Physiol. 2017 Jan 15;595(2):451-463. doi: 10.1113/JP271694. Epub 2016 May 5. Review. — View Citation

Yuan M, Li D, Zhang Z, Sun H, An M, Wang G. Endometriosis induces gut microbiota alterations in mice. Hum Reprod. 2018 Apr 1;33(4):607-616. doi: 10.1093/humrep/dex372. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Biological samples collection for establishment of the first National Microbiome Biobank Recruitment of 100 subjects (patients with recurrent cervicovaginitis, endometriosis, repeated implantation failures and healthy volunteers) to collect biological samples for establishment of the first National Microbiome Biobank through study completion, an average of 1 year
See also
  Status Clinical Trial Phase
Completed NCT01931670 - A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain Phase 3
Recruiting NCT05648669 - A Study to Evaluate Safety and Efficacy of Elagolix in Patients With Moderate to Severe Endometriosis-Associated Pain Phase 3
Recruiting NCT04081532 - The Effectiveness of Laparoscopic Treatment of Superficial Endometriosis for Managing Chronic Pelvic Pain N/A
Recruiting NCT06101303 - Endometriosis Pain
Completed NCT04665414 - Diagnosis of Adenomyosis Using Ultrasound, Elastography and MRI
Completed NCT03690765 - Study of Real Clinical Practice to Evaluate the Effects of Oral Dydrogesterone for Treatment of Confirmed Endometriosis
Recruiting NCT05153512 - ADOlescent DysmenoRrhea Endometriosis Assessment Magnetic Resonance Imaging (Adodream)
Active, not recruiting NCT04171297 - Ultrasound Evaluation of the Pelvis in Women With Suspected Endometriosis Scheduled for Laparoscopic Surgery
Recruiting NCT04172272 - The Influence of TAP Block in the Control of Postoperative Pain After Laparotomy for Gynecological Procedures N/A
Recruiting NCT04565470 - Strategies of Self-management of Endometriosis Symptoms
Completed NCT03613298 - Treatment by HIFU With Focal One® of Posterior Deep Infiltrating Endometriosis Lesions With Intestinal Involvement. N/A
Not yet recruiting NCT05568940 - Evaluating Tibolone Add-back in Patients With Endometriosis and Fibroids
Not yet recruiting NCT03464799 - Does Immunotherapy Have a Role in the Management of Endometriosis?
Active, not recruiting NCT03002870 - Characteristics of Patient Population With Endometriosis N/A
Withdrawn NCT03272360 - Endometriosis Biomarker Discovery Study N/A
Completed NCT02973854 - Activation of the Sphingosine-1-phosphate (S1P) to S1P1 Receptor Subtype (S1PR1) Axis in Patients With Endometriosis: Identification of Potential Relevant Biomarkers to Diagnose and Treat
Recruiting NCT02481739 - Laparoscopic Surgical Management of Endometriosis on Fertility N/A
Active, not recruiting NCT02754648 - Three Different Laparoscopic Approaches for Ovarian Endometrioma and the Effect on Ovarian Reserve N/A
Completed NCT06106932 - GnRH-a on Angiogenesis of Endometriosis N/A
Completed NCT02387931 - Supplementation in Adolescent Girls With Endometriosis Phase 4